IM Cannabis Corp. (IMCC)
USD 1.44
(-3.36%)
USD 1.44
(-3.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 22.63 Million CAD | -46.49% |
| 2022 | 35.56 Million CAD | -26.94% |
| 2021 | 48.68 Million USD | 160.17% |
| 2020 | 18.71 Million CAD | 77.01% |
| 2019 | 10.57 Million CAD | 285.28% |
| 2018 | 2.74 Million CAD | 2096.87% |
| 2017 | 124.9 Thousand CAD | 719.05% |
| 2016 | 15.25 Thousand CAD | -65.71% |
| 2015 | 44.47 Thousand CAD | -79.89% |
| 2014 | 221.17 Thousand CAD | 1.01% |
| 2013 | 218.96 Thousand CAD | -27.62% |
| 2012 | 302.5 Thousand CAD | -42.08% |
| 2011 | 522.29 Thousand CAD | -22.71% |
| 2010 | 675.72 Thousand CAD | -48.82% |
| 2009 | 1.32 Million CAD | -14.78% |
| 2008 | 1.54 Million CAD | 321.98% |
| 2007 | 367.11 Thousand CAD | 4.55% |
| 2006 | 351.13 Thousand CAD | 0.19% |
| 2005 | 350.48 Thousand CAD | -17.51% |
| 2004 | 424.86 Thousand CAD | 3.8% |
| 2003 | 409.31 Thousand CAD | 120.0% |
| 2002 | -2.04 Million CAD | 0.0% |
| 2001 | - CAD | 0.0% |
| 2000 | - CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| 1998 | - CAD | 0.0% |
| 1997 | - CAD | 0.0% |
| 1996 | - CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.73 Million CAD | -127.33% |
| 2024 Q1 | 7.4 Million CAD | 23.36% |
| 2023 Q3 | 16.01 Million CAD | 228.58% |
| 2023 Q2 | 4.87 Million CAD | -21.87% |
| 2023 FY | 19.03 Million CAD | -46.49% |
| 2023 Q4 | 6 Million CAD | -62.5% |
| 2023 Q1 | 6.23 Million CAD | -53.14% |
| 2022 Q2 | 17.25 Million CAD | 20.08% |
| 2022 Q1 | 14.37 Million CAD | -10.36% |
| 2022 FY | 35.56 Million CAD | -26.94% |
| 2022 Q4 | 13.31 Million CAD | 77.99% |
| 2022 Q3 | 7.47 Million CAD | -56.66% |
| 2021 Q1 | 6.73 Million CAD | -2.28% |
| 2021 Q4 | 16.03 Million USD | 1.67% |
| 2021 Q2 | 10.14 Million CAD | 50.74% |
| 2021 FY | 48.68 Million USD | 160.17% |
| 2021 Q3 | 15.77 Million CAD | 55.38% |
| 2020 Q1 | 2.92 Million CAD | 225.7% |
| 2020 FY | 18.71 Million CAD | 77.01% |
| 2020 Q2 | 4.84 Million CAD | 65.4% |
| 2020 Q4 | 6.89 Million CAD | 70.04% |
| 2020 Q3 | 4.05 Million CAD | -16.33% |
| 2019 Q1 | 10.75 Thousand CAD | -42.99% |
| 2019 Q4 | 899 Thousand CAD | -70.92% |
| 2019 Q3 | 3.09 Million CAD | 732364.45% |
| 2019 FY | 10.57 Million CAD | 285.28% |
| 2019 Q2 | 422.00 CAD | -96.08% |
| 2018 Q2 | 60.94 Thousand CAD | -34.41% |
| 2018 Q4 | 18.86 Thousand CAD | -97.47% |
| 2018 Q1 | 92.91 Thousand CAD | 360.2% |
| 2018 FY | 2.74 Million CAD | 2096.87% |
| 2018 Q3 | 747 Thousand CAD | 1125.78% |
| 2017 Q3 | 10.37 Thousand CAD | 627.72% |
| 2017 FY | 124.9 Thousand CAD | 719.05% |
| 2017 Q1 | 15.25 Thousand CAD | 0.0% |
| 2017 Q2 | 1425.00 CAD | -90.66% |
| 2017 Q4 | 20.19 Thousand CAD | 94.71% |
| 2016 FY | 15.25 Thousand CAD | -65.71% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 FY | 44.47 Thousand CAD | -79.89% |
| 2014 Q1 | 28.12 Thousand CAD | -60.61% |
| 2014 Q3 | 76.64 Thousand CAD | 166.31% |
| 2014 Q4 | 35.03 Thousand CAD | -54.3% |
| 2014 Q2 | 28.78 Thousand CAD | 2.34% |
| 2014 FY | 221.17 Thousand CAD | 1.01% |
| 2013 Q4 | 71.39 Thousand CAD | 16.87% |
| 2013 Q2 | 58.35 Thousand CAD | -26.66% |
| 2013 Q1 | 79.56 Thousand CAD | 3.89% |
| 2013 Q3 | 61.08 Thousand CAD | 4.68% |
| 2013 FY | 218.96 Thousand CAD | -27.62% |
| 2012 Q4 | 76.58 Thousand CAD | 1.57% |
| 2012 Q1 | 120.63 Thousand CAD | 47.13% |
| 2012 Q2 | 70.94 Thousand CAD | -41.19% |
| 2012 Q3 | 75.4 Thousand CAD | 6.28% |
| 2012 FY | 302.5 Thousand CAD | -42.08% |
| 2011 Q4 | 81.99 Thousand CAD | -37.43% |
| 2011 Q3 | 131.04 Thousand CAD | -30.53% |
| 2011 Q2 | 188.62 Thousand CAD | -16.2% |
| 2011 Q1 | 225.07 Thousand CAD | 111.35% |
| 2011 FY | 522.29 Thousand CAD | -22.71% |
| 2010 Q4 | 106.49 Thousand CAD | -54.16% |
| 2010 Q1 | 301.69 Thousand CAD | -56.22% |
| 2010 Q2 | 111.82 Thousand CAD | -62.94% |
| 2010 Q3 | 232.33 Thousand CAD | 107.77% |
| 2010 FY | 675.72 Thousand CAD | -48.82% |
| 2009 Q4 | 689.09 Thousand CAD | 317.73% |
| 2009 Q2 | 164.42 Thousand CAD | -29.51% |
| 2009 Q1 | 233.24 Thousand CAD | -7.16% |
| 2009 FY | 1.32 Million CAD | -14.78% |
| 2009 Q3 | 164.96 Thousand CAD | 0.33% |
| 2008 Q4 | 251.22 Thousand CAD | 105.01% |
| 2008 Q3 | 122.54 Thousand CAD | -86.56% |
| 2008 Q2 | 912.13 Thousand CAD | 767.41% |
| 2008 FY | 1.54 Million CAD | 321.98% |
| 2008 Q1 | 105.15 Thousand CAD | -15.8% |
| 2007 Q2 | 62.91 Thousand CAD | -46.6% |
| 2007 FY | 367.11 Thousand CAD | 4.55% |
| 2007 Q1 | 117.82 Thousand CAD | 114.77% |
| 2007 Q4 | 124.89 Thousand CAD | 55.49% |
| 2007 Q3 | 80.32 Thousand CAD | 27.67% |
| 2006 Q4 | 54.86 Thousand CAD | -53.38% |
| 2006 Q3 | 117.67 Thousand CAD | 93.65% |
| 2006 FY | 351.13 Thousand CAD | 0.19% |
| 2006 Q1 | 105.66 Thousand CAD | 75.93% |
| 2006 Q2 | 60.76 Thousand CAD | -42.49% |
| 2005 FY | 350.48 Thousand CAD | -17.51% |
| 2005 Q4 | 60.06 Thousand CAD | -40.3% |
| 2005 Q3 | 100.59 Thousand CAD | 19.54% |
| 2005 Q2 | 84.15 Thousand CAD | -57.15% |
| 2005 Q1 | 196.37 Thousand CAD | 242.76% |
| 2004 Q1 | 196.22 Thousand CAD | 309.09% |
| 2004 FY | 424.86 Thousand CAD | 3.8% |
| 2004 Q2 | 83.45 Thousand CAD | -57.47% |
| 2004 Q3 | 87.73 Thousand CAD | 5.13% |
| 2004 Q4 | 57.29 Thousand CAD | -34.7% |
| 2003 Q2 | 54.59 Thousand CAD | 121.95% |
| 2003 Q3 | 115.64 Thousand CAD | 111.82% |
| 2003 Q1 | -248.73 Thousand CAD | -308.24% |
| 2003 FY | 409.31 Thousand CAD | 120.0% |
| 2003 Q4 | 47.96 Thousand CAD | -58.52% |
| 2002 FY | -2.04 Million CAD | 0.0% |
| 2002 Q3 | -659.38 Thousand CAD | -1111.77% |
| 2002 Q1 | -38.54 Thousand CAD | 0.0% |
| 2002 Q4 | -60.92 Thousand CAD | 90.76% |
| 2002 Q2 | -54.41 Thousand CAD | -41.17% |
| 2001 Q4 | - CAD | 0.0% |
| 2001 Q2 | - CAD | 0.0% |
| 2001 FY | - CAD | 0.0% |
| 2001 Q1 | - CAD | 0.0% |
| 2001 Q3 | - CAD | 0.0% |
| 2000 Q1 | -500 Thousand CAD | 0.0% |
| 2000 Q4 | - CAD | 0.0% |
| 2000 Q3 | - CAD | 0.0% |
| 2000 Q2 | - CAD | 100.0% |
| 2000 FY | - CAD | 0.0% |
| 1999 Q3 | - CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| 1999 Q4 | - CAD | 0.0% |
| 1999 Q2 | - CAD | 0.0% |
| 1999 Q1 | - CAD | 0.0% |
| 1998 Q3 | - CAD | 0.0% |
| 1998 FY | - CAD | 0.0% |
| 1998 Q4 | - CAD | 0.0% |
| 1998 Q1 | - CAD | 0.0% |
| 1998 Q2 | - CAD | 0.0% |
| 1997 Q3 | - CAD | 0.0% |
| 1997 Q2 | - CAD | 0.0% |
| 1997 FY | - CAD | 0.0% |
| 1997 Q4 | - CAD | 0.0% |
| 1996 FY | - CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 590 Million USD | 96.163% |
| PainReform Ltd. | 9.58 Million USD | -136.206% |
| Alvotech | 285.43 Million USD | 92.069% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 85.781% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 88.449% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 49.53% |
| Journey Medical Corporation | 54.59 Million USD | 58.534% |
| Dynavax Technologies Corporation | 219.14 Million USD | 89.67% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 91.674% |
| Bright Green Corporation | 8.25 Million USD | -174.305% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 93.064% |
| Embecta Corp. | 528.4 Million USD | 95.716% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -72.487% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -72.487% |
| SCYNEXIS, Inc. | 51.84 Million USD | 56.338% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -27.119% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -2868.949% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -637.589% |
| Alpha Teknova, Inc. | 45.85 Million USD | 50.636% |
| Safety Shot Inc | 12.1 Million USD | -86.941% |
| Procaps Group, S.A. | 199.47 Million USD | 88.651% |
| Cosmos Health Inc. | 26.18 Million USD | 13.532% |
| Theratechnologies Inc. | 72.75 Million USD | 68.885% |
| Harrow Health, Inc. | 89.97 Million USD | 74.839% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -139.657% |
| Biofrontera Inc. | 39.95 Million USD | 43.347% |
| DURECT Corporation | 43.71 Million USD | 48.215% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 95.721% |
| Cronos Group Inc. | 96.7 Million USD | 76.592% |
| OptiNose, Inc. | 85.1 Million USD | 73.399% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 90.247% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 42.181% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 336.774% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 92.794% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -132.642% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 47.403% |
| Radius Health, Inc. | 265.92 Million USD | 91.487% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -63.547% |
| ProPhase Labs, Inc. | 37.85 Million USD | 40.193% |
| Phibro Animal Health Corporation | 260.29 Million USD | 91.303% |
| Procaps Group S.A. | 187.24 Million USD | 87.91% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -130.412% |
| Viatris Inc. | 5.96 Billion USD | 99.621% |
| Rockwell Medical, Inc. | 15.37 Million USD | -47.249% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 62.169% |
| SIGA Technologies, Inc. | 22.04 Million USD | -2.699% |
| Tilray Brands, Inc. | 251.35 Million USD | 90.994% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 53.836% |
| Shineco, Inc. | 17.94 Million USD | -26.131% |
| PetIQ, Inc. | 192.72 Million USD | 88.254% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -467.207% |
| Incannex Healthcare Limited | 30.05 Million USD | 24.673% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.582% |
| Alimera Sciences, Inc. | 62.64 Million USD | 63.861% |
| Assertio Holdings, Inc. | 368.58 Million USD | 93.858% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -284.636% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -6.939% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -7.584% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 86.277% |
| Hempacco Co., Inc. | 7.59 Million USD | -198.008% |
| Talphera, Inc. | 11.99 Million USD | -88.744% |
| Alvotech | 285.43 Million USD | 92.069% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 83.912% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 93.436% |
| Currenc Group, Inc. | 24 Million USD | 5.683% |
| Kamada Ltd. | 45.42 Million USD | 50.165% |
| Indivior PLC | 911 Million USD | 97.515% |
| Evoke Pharma, Inc. | 12.4 Million USD | -82.423% |
| Flora Growth Corp. | 10.57 Million USD | -113.99% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -7.584% |
| Evolus, Inc. | 189.75 Million USD | 88.07% |
| HUTCHMED (China) Limited | 436.23 Million USD | 94.811% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 85.313% |
| Akanda Corp. | 3.48 Million USD | -549.862% |